Brief: Combigene And Spark Therapeutics Enter Licensing Agreement For Gene Therapy Candidate CG01

Larkberget AB

12/10/2021 06:04

Oct 12 (Reuters) - Combigene AB  COMBI.ST :
    * COMBIGENE AND SPARK THERAPEUTICS ENTER EXCLUSIVE, GLOBAL
LICENSING AGREEMENT FOR GENE THERAPY CANDIDATE CG01
    * UNDER TERMS OF AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO
$328.5
MILLION EXCLUDING ROYALTIES
    * IS ELIGIBLE TO RECEIVE UP TO $328.5 MILLION EXCLUDING
ROYALTIES,
WITH $8.5 MILLION UPON SIGNING, UP TO $50 MILLION AT PRECLINICAL
AND CLINICAL MILESTONES
    * WILL ALSO BE REIMBURSED FOR CERTAIN AUTHORIZED RESEARCH
AND
DEVELOPMENT EXPENSES
    * DEAL PROVIDES SPARK WITH EXCLUSIVE WORLD-WIDE LICENSE TO
DEVELOP, MANUFACTURE AND COMMERCIALIZE CG01

Source text for Eikon:  ID:nMFN6Kk1gm 
Further company coverage:  COMBI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))